The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
|Videos|June 29, 2020
Rapid Readouts: Initial Results of the Phase III BOSTON Study
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
2
CNS Control and Daily Tolerability Guide Treatment Sequencing in HER2-Mutated NSCLC
3
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
4
Tabelecleucel BLA Is Resubmitted to FDA for EBV+ Post-Transplant Lymphoproliferative Disease
5